$2.2 Billion is the total value of Rock Springs Capital Management LP's 145 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TFX | New | TELEFLEX INC | $22,829,000 | – | 91,750 | +100.0% | 1.04% | – |
| SYK | New | STRYKER CORP | $19,587,000 | – | 126,500 | +100.0% | 0.89% | – |
| HOLX | New | HOLOGIC INC | $14,321,000 | – | 335,000 | +100.0% | 0.65% | – |
| ODT | New | ODONATE THERAPEUTICS INC | $10,250,000 | – | 410,000 | +100.0% | 0.46% | – |
| INGN | New | INOGEN INC | $9,526,000 | – | 80,000 | +100.0% | 0.43% | – |
| ABLX | New | ABLYNX NVsponsored adr | $6,248,000 | – | 250,000 | +100.0% | 0.28% | – |
| SPRO | New | SPERO THERAPEUTICS INC | $6,169,000 | – | 525,000 | +100.0% | 0.28% | – |
| DVA | New | DAVITA INC | $5,787,000 | – | 80,100 | +100.0% | 0.26% | – |
| HRTX | New | HERON THERAPEUTICS INC | $4,525,000 | – | 250,000 | +100.0% | 0.20% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $3,285,000 | – | 180,000 | +100.0% | 0.15% | – |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $2,078,000 | – | 71,500 | +100.0% | 0.09% | – |
| PRTA | New | PROTHENA CORP PLCcall | $937,000 | – | 25,000 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.